Global electronics contract manufacturer Kimball Solutions (NASDAQ: KE) reported calendar Q3 2026 (fiscal Q1 2027) results topping the market’s revenue expectations, with sales up 6.9% year on year to $390.8 million. The company expects the full year’s revenue to be around $1.55 billion, close to analysts’ estimates. Its non-GAAP profit of $0.25 per share was 37% below analysts’ consensus estimates.

Is now the time to buy KE? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Kimball Solutions experienced a mixed quarter, with revenue surpassing Wall Street expectations but adjusted earnings per share coming in significantly below consensus. Management attributed the revenue strength to robust organic sales growth, especially within the medical segment, as well as early contributions from the Helvoet acquisition. CEO Ric Phillips noted, “The organic growth was in line with expectations and driven by a high single-digit increase in medical sales.” However, margin pressure persisted due to higher component costs and ongoing investments in new facilities, which CFO Jana Croom indicated would weigh on near-term profitability.

Looking ahead, Kimball Solutions’ full-year outlook is anchored by continued momentum in medical, integration of Helvoet, and targeted expansion in the Indianapolis facility. Management expects production to ramp in the new medical CDMO facility, with CFO Jana Croom emphasizing core medical as a key growth driver and noting, “We are looking at double-digit growth, just really driving it.” However, they also acknowledged ongoing inflationary pressures and supply chain challenges, particularly in electronic components and memory, may moderate margin gains.

Key insights from management’s remarks

Management pointed to strong medical demand, Helvoet integration, and ongoing cost pressures as the largest influences on performance and guidance.

• Medical segment acceleration: The medical business delivered high single-digit organic growth, supported by new product launches in drug delivery, respiratory care, and patient monitoring. Management highlighted this as the strongest area of expansion and a primary reason for overall sales growth.
• Helvoet acquisition synergy: Integration of Helvoet Polymer Technologies, acquired to bolster Kimball’s medical CDMO (contract development and manufacturing organization) capabilities, brought meaningful top-line contribution and is expected to ramp through the year. CEO Ric Phillips stated customer interest and synergy opportunities are “at a high level.”
• Automotive mix shift: While overall automotive sales rose, management cited that steering systems in Europe and new program ramps in China drove growth, partially offsetting ongoing softness in North American EV demand.
• Margin headwinds: Gross margin remained flat as favorable mix in medical and industrial was offset by inflation in material costs and start-up expenses for the new Indianapolis facility. CFO Jana Croom explained that these investments will weigh on margins until production volumes increase.
• Inventory and cash dynamics: Inventory increased to support higher production, reflecting the return to growth, but cash conversion days remained at a multi-year low, signaling underlying operational discipline despite the inventory build.

Drivers of future performance

Kimball Solutions’ outlook is driven by medical growth, facility ramp-up, and the pace of margin recovery amid cost inflation.

• Medical momentum and capacity: Management expects double-digit growth in medical, underpinned by new customer wins and increasing utilization of the Indianapolis CDMO facility, which is scheduled to start production soon. The Helvoet integration is seen as a catalyst for broadening Kimball’s healthcare customer base and solution set.
• Margin recovery timing: While revenue growth is anticipated, management cautioned that margin improvement will lag due to continued cost inflation in electronic components and ramp-related expenses. They plan to update guidance on profitability as volumes stabilize and cost pressures become clearer.
• Portfolio balance strategy: The company continues to prioritize diversifying across medical, industrial, and automotive verticals, with a stated focus on reducing dependency on cyclical markets. This strategic shift is intended to support more consistent long-term growth and reduce volatility from sector-specific headwinds.

Catalysts in upcoming quarters

Looking forward, the StockStory team will be watching (1) the pace of new program wins and production ramp-up at the Indianapolis medical CDMO facility, (2) evidence of successful synergy capture and revenue growth from the Helvoet integration, and (3) any improvement in gross margin as inflationary pressures and startup costs subside. Execution in portfolio diversification and ongoing demand in medical will also be key to monitoring progress.

Kimball Solutions currently trades at $20.89, down from $25.86 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.